Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer

Autor: Pernelle Lavaud, Bernadett Szabados, Rafael Morales-Barrera, Alfonso Gomez De Liano Lista, Pablo Maroto, Marine Gross Goupil, Andrea Necchi, Thomas Powles, Nick van Dijk, Alain Ravaud, Michiel S. van der Heijden, Joan Carles, Daniele Raggi, Patrizia Giannatempo, Ignacio Duran, Yohann Loriot, Teresa Alonso Gordoa, Daniel Castellano, Georgia Anguera Palacios, Félix Lefort, Guillermo de Velasco Oria de Rueda

Publikováno v: EUROPEAN UROLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Background: Immune checkpoint inhibitors (ICIs) are approved for first-line (cisplatin unfit, PD-L1+) and platinum-refractory urothelial carcinoma (UC). Still, most patients experience progressive disease (PD) as the best response. Although higher re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43a0ba091aad15d616915b92eba24e2
https://pubmed.ncbi.nlm.nih.gov/33153815

Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.

Autor: Guilhem-Ducléon G; Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux, France., Dalban C; Department of Clinical Research and Innovation, Centre de Lutte Contre Le Cancer, Centre Léon Bérard, Lyon, France., Negrier S; University Lyon I, Centre Léon Bérard, Lyon, France., Gravis G; Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France., Laguerre B; Department of Medical Oncology, Centre Eugene Marquis, Rennes, France., Chevreau C; Department of Medical Oncology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France., Oudard S; Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France., Barthelemy P; Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Ladoire S; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France., Boughalem E; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 49055 Angers, France., Borchiellini D; Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France., Linassier C; Department of Medical Oncology, CHU Bretonneau et Université de Tours, Tours, France., Nenan S; Unicancer, Paris, France., Flippot R; Department of Medical Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France., Albiges L; Department of Medical Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France., Goupil MG; Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux, France. Electronic address: marine.gross-goupil@chu-bordeaux.fr.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Dec; Vol. 21 (6), pp. 643-652. Date of Electronic Publication: 2023 Jul 20.

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.

Autor: Delanoy N; European Georges Pompidou Hospital, Paris, France., Hardy-Bessard AC; Centre Armoricain d'Oncologie, CARIO, Plerin, France., Efstathiou E; Alexandra Hospital, University of Athens, Athens, Greece; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Le Moulec S; Bergonie Institute, Bordeaux, France., Basso U; Istituto Oncologico Veneto Iov IRCCS, Padova, Italy., Birtle A; Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK; University Hospitals of Morecombe Bay, NHS Foundation Trust, Lancaster, UK., Thomson A; Royal Cornwall Hospitals NHS Trust, Truro, UK., Krainer M; Medical university of Vienna, Vienna, Austria., Guillot A; Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez, France., De Giorgi U; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy., Hasbini A; Clinique Pasteur, Brest, France., Daugaard G; Copenhagen University Hospital, Copenhagen, Denmark., Bahl A; University Hospitals Bristol NHS Foundation Trust, Bristol, UK., Chowdhury S; Guy's and St. Thomas' Hospital NHS Trust, London, UK., Caffo O; Santa Ciara Hospital, Trento, Italy., Beuzeboc P; Institut Curie, Paris, France., Spaeth D; Gentilly Oncology Centre, Nancy, France., Eymard JC; Jean Godinot Institute, Reims, France., Fléchon A; Centre Léon Bérard, Lyon, France., Alexandre J; Hôpital Cochin, Paris, France., Helissey C; Hôpital d'Instruction des armées, Bégin, Saint Mandé, France., Butt M; Hull and East Yorkshire Hospitals NHS Trust, Hull, UK., Priou F; CHD Vendee-Hopital Les Oudairies, La Roche Sur Yon, France., Lechevallier É; La Timone Hospital, Marseille, France., Deville JL; La Timone Hospital, Marseille, France., Goupil MG; CHU de Bordeaux, Bordeaux, France., Morales R; University Hospital Vall d'Hebron, Barcelona, Spain., Thiery-Vuillemin A; CHRU de Besançon, Besançon, France., Gavrikova T; Centre Hospitalier de Sens, Sens, France., Barthelemy P; Hôpital Civil, Strasbourg, France., Sella A; Assaf Harofeh Medical Centre, Zerifin, Israel., Fizazi K; Gustave Roussy, University of Paris Sud, Villejuif, France., Baciarello G; Gustave Roussy, University of Paris Sud, Villejuif, France., Fererro JM; Centre Antoine Lacassagne, Nice, France., Laguerre B; Centre Eugène Marquis, Rennes, France., Verret B; European Georges Pompidou Hospital, Paris, France., Hans S; European Georges Pompidou Hospital, Paris, France., Oudard S; European Georges Pompidou Hospital, Paris, France. Electronic address: stephane.oudard@aphp.fr.

Publikováno v: European urology oncology [Eur Urol Oncol] 2018 Dec; Vol. 1 (6), pp. 467-475. Date of Electronic Publication: 2018 Jun 08.